Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Helga Fibiger Munch-Petersen"'
Autor:
Konstantinos Dimopoulos, Alexandra Søgaard Helbo, Helga Fibiger Munch‐Petersen, Lene Sjö, Jesper Christensen, Lasse Sommer Kristensen, Fazila Asmar, Niels Emil Ulrich Hermansen, Casey O'Connel, Peter Gimsing, Gangning Liang, Kirsten Grønbæk
Publikováno v:
Molecular Oncology, Vol 12, Iss 2, Pp 180-195 (2018)
Thalidomide and its derivatives, lenalidomide and pomalidomide (also known as IMiDs), have significantly changed the treatment landscape of multiple myeloma, and the recent discovery of cereblon (CRBN) as their direct biological target has led to a d
Externí odkaz:
https://doaj.org/article/46bc59ffdccb4852a3e3e53450c41bd8
Autor:
Julia Meade, Katharina Wimmer, Maria Anna Misiakou, Birgitte Bertelsen, Hendrik Gottschling, Johannes Zschocke, Astrid Sehested, David Scheie, Helga Fibiger Munch-Petersen, Richard Gallon, Matthias Schmuth, Olga Østrup, Linea Melchior, Elena Kessler, Reetesh K. Pai, Tomasz Sarosiek
Publikováno v:
Sehested, A, Meade, J, Scheie, D, Østrup, O, Bertelsen, B, Misiakou, M A, Sarosiek, T, Kessler, E, Melchior, L C, Munch-Petersen, H F, Pai, R K, Schmuth, M, Gottschling, H, Zschocke, J, Gallon, R & Wimmer, K 2022, ' Constitutional POLE variants causing a phenotype reminiscent of constitutional mismatch repair deficiency ', Human Mutation, vol. 43, no. 1, pp. 85-96 . https://doi.org/10.1002/humu.24299
Heterozygous POLE or POLD1 germline pathogenic variants (PVs) cause polymerase proofreading associated polyposis (PPAP), a constitutional polymerase proofreading deficiency that typically presents with colorectal adenomas and carcinomas in adulthood.
Autor:
Natacha Würtz Yazdanfard, Lauge Hjorth Mikkelsen, Nille Behrendt, Katrine Fuglsang, Jan Blaakær, Lisbet Rosenkrantz Hölmich, Ligita Paskeviciute Frøding, Helga Fibiger Munch-Petersen, Steffen Heegaard
Publikováno v:
Yazdanfard, N W, Mikkelsen, L H, Behrendt, N, Fuglsang, K, Blaakær, J, Hölmich, L R, Frøding, L P, Munch-Petersen, H F & Heegaard, S 2022, ' Vaginal melanoma in Denmark from 1980 to 2018 : A population-based study based on genetic profile and survival ', Gynecologic Oncology, vol. 165, no. 1, pp. 53-59 . https://doi.org/10.1016/j.ygyno.2022.01.028
OBJECTIVE: To investigate the clinical, pathological, and genetic characteristics of patients with vaginal melanoma in a nationwide setting.MATERIALS/METHODS: All patients diagnosed with vaginal melanoma from 1980 to 2018 were collected by searching
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65ff82fe469e2d2f436a373ceb90c5ec
https://pure.au.dk/portal/da/publications/vaginal-melanoma-in-denmark-from-1980-to-2018(1a545417-445e-4f92-b9dd-2a00f5ee5351).html
https://pure.au.dk/portal/da/publications/vaginal-melanoma-in-denmark-from-1980-to-2018(1a545417-445e-4f92-b9dd-2a00f5ee5351).html
Autor:
Nicolai Krogh, Kirsten Grønbæk, Christophe Côme, Helga Fibiger Munch-Petersen, Henrik Nielsen, Fazila Asmar
Publikováno v:
Krogh, N, Asmar, F, Côme, C R M, Fibiger Munch-Petersen, H, Grønbæk, K & Nielsen, H 2020, ' Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets ', NAR Cancer, vol. 2, no. 4, zcaa035 . https://doi.org/10.1093/narcan/zcaa035
NAR Cancer
NAR Cancer
Cancer cells are addicted to ribosome biogenesis and high levels of translation. Thus, differential inhibition of cancer cells can be achieved by targeting aspects of ribosome biogenesis or ribosome function. Using RiboMeth-seq for profiling of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73a27f27d0ffd76d1252634bfe14c530
https://curis.ku.dk/ws/files/257706723/zcaa035.pdf
https://curis.ku.dk/ws/files/257706723/zcaa035.pdf
Autor:
Elisabeth Ralfkiaer, Konstantinos Dimopoulos, Peter Gimsing, Helga Fibiger Munch-Petersen, Christian Winther Eskelund, Kirsten Grønbæk, Lene Dissing Sjö
Publikováno v:
Leukemia & Lymphoma. 60:180-188
The immunomodulatory drug thalidomide, and its analogs, lenalidomide, and pomalidomide (IMiDs), have become essential components of the standard treatment for multiple myeloma (MM), and have led to significant improvement of survival in patients with
Autor:
Fazila Asmar, Casey O'Connel, Lasse Sommer Kristensen, Gangning Liang, Peter Gimsing, Helga Fibiger Munch-Petersen, Kirsten Grønbæk, Konstantinos Dimopoulos, Niels Emil Ulrich Hermansen, Alexandra Søgaard Helbo, Jesper Christensen, Lene Dissing Sjö
Publikováno v:
Dimopoulos, K, Søgaard Helbo, A, Fibiger Munch-Petersen, H, Sjö, L, Christensen, J, Sommer Kristensen, L, Asmar, F, Hermansen, N E U, O'Connel, C, Gimsing, P, Liang, G & Grønbaek, K 2018, ' Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner ', Molecular Oncology, vol. 12, no. 2, pp. 180-195 . https://doi.org/10.1002/1878-0261.12157
Molecular Oncology
Molecular Oncology, Vol 12, Iss 2, Pp 180-195 (2018)
Dimopoulos, K, Søgaard Helbo, A, Fibiger Munch-Petersen, H, Sjö, L, Christensen, J, Sommer Kristensen, L, Asmar, F, Hermansen, N E U, O'Connel, C, Gimsing, P, Liang, G & Grønbaek, K 2018, ' Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner ', Molecular Oncology, vol. 12, no. 2 . https://doi.org/10.1002/1878-0261.12157
Molecular Oncology
Molecular Oncology, Vol 12, Iss 2, Pp 180-195 (2018)
Dimopoulos, K, Søgaard Helbo, A, Fibiger Munch-Petersen, H, Sjö, L, Christensen, J, Sommer Kristensen, L, Asmar, F, Hermansen, N E U, O'Connel, C, Gimsing, P, Liang, G & Grønbaek, K 2018, ' Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner ', Molecular Oncology, vol. 12, no. 2 . https://doi.org/10.1002/1878-0261.12157
Thalidomide and its derivatives, lenalidomide and pomalidomide (also known as IMiDs), have significantly changed the treatment landscape of multiple myeloma, and the recent discovery of cereblon (CRBN) as their direct biological target has led to a d
Autor:
Florian P.Y. Barré, Christophe Côme, Frédéric Dewez, Britt S. R. Claes, Helga Fibiger Munch-Petersen, Berta Cillero-Pastor, Carine J. Peutz-Kootstra, Ron M. A. Heeren, Anders H. Lund, Kirsten Grønbæk
Publikováno v:
Analytical Chemistry
Analytical Chemistry, 90(24), 14198-14206. American Chemical Society
Barré, F P Y, Claes, B S R, Dewez, F, Peutz-Kootstra, C, Munch-Petersen, H F, Grønbæk, K, Lund, A H, Heeren, R M A, Côme, C & Cillero-Pastor, B 2018, ' Specific Lipid and Metabolic Profiles of R-CHOP-Resistant Diffuse Large B-Cell Lymphoma Elucidated by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and in Vivo Imaging ', Analytical Chemistry, vol. 90, no. 24, pp. 14198-14206 . https://doi.org/10.1021/acs.analchem.8b02910
Analytical Chemistry, 90(24), 14198-14206. American Chemical Society
Barré, F P Y, Claes, B S R, Dewez, F, Peutz-Kootstra, C, Munch-Petersen, H F, Grønbæk, K, Lund, A H, Heeren, R M A, Côme, C & Cillero-Pastor, B 2018, ' Specific Lipid and Metabolic Profiles of R-CHOP-Resistant Diffuse Large B-Cell Lymphoma Elucidated by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and in Vivo Imaging ', Analytical Chemistry, vol. 90, no. 24, pp. 14198-14206 . https://doi.org/10.1021/acs.analchem.8b02910
Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma. To treat this aggressive disease, R-CHOP, a combination of immunotherapy (R; rituximab) and chemotherapy (CHOP; cyclophosphamide, doxorubicin, vincristine, and pred